<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21154" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Enteroglucagon</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sarwal</surname>
            <given-names>Dhruv</given-names>
          </name>
          <aff>Government Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bordoni</surname>
            <given-names>Bruno</given-names>
          </name>
          <aff>Foundation Don Carlo Gnocchi IRCCS</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dhruv Sarwal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bruno Bordoni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21154.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Enteroglucagon is a molecule discovered in the human intestine. The historical belief was that it was an extra-pancreatic isoform of glucagon. Glucagon-like substances in the intestine were first described by Sutherland and De Duve, who identified them in preparations from the intestinal mucosa.<xref ref-type="bibr" rid="article-21154.r1">[1]</xref>&#x000a0;These substances became known as peptides with glucagon-like immunoreactivity (GLI) due to patterns of immunoreactivity shared with glucagon.<xref ref-type="bibr" rid="article-21154.r2">[2]</xref>&#x000a0;Subsequent sequencing studies&#x000a0;revealed that enteroglucagons consisted of several different molecules derived within the L-cells (enteroendocrine cells) of the intestine by post-translational modification of the preproglucagon polypeptide (see <bold>Image.</bold> Intestinal&#x000a0;Epithelium With&#x000a0;L&#x000a0;Cells Present).<xref ref-type="bibr" rid="article-21154.r3">[3]</xref>&#x000a0;L-cells or enteroendocrine cells have been localized most specifically to the ileum and the colon, although they occur sporadically in other parts of the intestine.<xref ref-type="bibr" rid="article-21154.r4">[4]</xref></p>
      </sec>
      <sec id="article-21154.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>The preproglucagon polypeptides play key roles in intestinal and systemic metabolism:</p>
        <list list-type="bullet">
          <list-item>
            <p>Glicentin</p>
          </list-item>
          <list-item>
            <p>Glucagon-like peptide 1 (GLP-1)</p>
          </list-item>
          <list-item>
            <p>Glucagon-like peptide 2 (GLP-2)</p>
          </list-item>
          <list-item>
            <p>Oxyntomodulin</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21154.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>The preproglucagon gene is the precursor to glucagon and is shared between the A-cells of the pancreatic islets of Langerhans and the L-cells of the intestine. Within the L-cells, the processing of preproglucagon polypeptide forms glicentin, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), and glicentin is then further cleaved to produce oxyntomodulin, with a leftover fragment called glicentin-related polypeptide (GRPP).<xref ref-type="bibr" rid="article-21154.r5">[5]</xref>&#x000a0;GLP-1 undergoes further processing, with the removal of amino acids from the N-terminus, to form the molecule GLP-1 (7-36), which significantly promotes insulin release from the pancreatic islets. This insulinotropic effect is active even at lower blood glucose levels. It is much more potent than the glucose-dependent insulinotropic peptide (GIP, previously known as a gastric-inhibitory peptide). Exenatide, a synthetic GLP-1 receptor agonist, was developed after the discovery of Exendin-4, a molecule of the glucagon superfamily of hormones, in the saliva of the Gila monster, which showed potent pancreatic insulinotropic effects in studies on animals, thus motivating the development of a new class of anti-diabetic medication.<xref ref-type="bibr" rid="article-21154.r6">[6]</xref>&#x000a0;The gene that codes for glicentin is on chromosome 2 (6 exons, 5 introns) and is found in the alpha cells of the pancreas and the intestinal or intestinal L cells.</p>
      </sec>
      <sec id="article-21154.s4" sec-type="Development">
        <title>Development</title>
        <p>In a 1991 study, researchers highlighted the presence of enteroglucagon/glicentin in a 10-week-old human fetus in pancreatic cells.</p>
      </sec>
      <sec id="article-21154.s5" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>Organ systems involved with enteroglucagon include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Glicentin (69 amino acids) is present in alpha cells of the pancreas, intestinal L cells (duodenum, rectum, distal ileum, proximal colon, caecum, proximal jejunum). Researchers have also found the glicentin gene in the central nervous system.</p>
          </list-item>
          <list-item>
            <p>GLP-1 (30 amino acids) is also in the alpha cells of the pancreas, L cells of the intestine (proximal small intestine, colon, and distal ileum), and in the central nervous system (nucleus tractus solitaries of the brain stem).</p>
          </list-item>
          <list-item>
            <p>GLP-2 (33 amino acids) is in the L cells of the intestine (colon and distal small intestine).</p>
          </list-item>
          <list-item>
            <p>Oxyntomodulin (37 amino acids) is likewise present in the L cells of the intestine.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21154.s6" sec-type="Function">
        <title>Function</title>
        <p>GLP-1 belongs to a class of molecules known as &#x0201c;incretins,&#x0201d; molecules that stimulate a decrease in blood glucose levels. The release of these molecules depends on the oral intake of glucose and other nutrients. This contributes to the &#x0201c;incretin effect,&#x0201d; a phenomenon by which oral glucose ingestion induces a greater increase in insulin release than an intravenous glucose load.<xref ref-type="bibr" rid="article-21154.r7">[7]</xref>&#x000a0;GLP-1 also participates in the &#x0201c;ileal-brake&#x0201d; effect, a mechanism by which the small intestine, in the presence of unabsorbed nutrients, exerts negative feedback on gastric emptying and gut motility to allow better digestion and absorption of these nutrients.<xref ref-type="bibr" rid="article-21154.r8">[8]</xref>&#x000a0;GLP-2 is involved in proliferative effects on small intestine mucosa.<xref ref-type="bibr" rid="article-21154.r9">[9]</xref>&#x000a0;These include hypertrophy of the epithelium and villi accompanied by increased mucosal blood flow at the cellular level, with evidence of hypertrophy also evident in gross anatomy in the form of increased mucosal folds and an increase in the caliber of the bowel. Glicentin shows some glucagon-like activity, while the roles of oxyntomodulin&#x000a0;and GRPP in humans are currently unclear.<xref ref-type="bibr" rid="article-21154.r10">[10]</xref><xref ref-type="bibr" rid="article-21154.r11">[11]</xref> However, studies are ongoing to determine their effects on diabetes and obesity.&#x000a0;According to some authors, oxyntomodulin reduces the sense of appetite, increases metabolism, and helps maintain systemic glucose homeostasis.</p>
      </sec>
      <sec id="article-21154.s7" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>GLP-1 acts on the GLP-1 receptor (GLP-1R), which belongs to the class of G-protein coupled receptors (GPCRs).<xref ref-type="bibr" rid="article-21154.r12">[12]</xref>&#x000a0;The GLP-1R has a Gs subunit responsible for activating the intracellular enzyme adenylyl cyclase, which is the catalyst for converting ATP to cAMP. This molecule is the second messenger for GLP-1 and GLP-2 and mediates further downstream effects of these peptides. After release, GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) to GLP-1 (9&#x02013;36) amide.<xref ref-type="bibr" rid="article-21154.r13">[13]</xref>&#x000a0;DPP-4 is widely expressed by endothelial cells on their surface, especially those neighboring GLP-1 secretion sites, and degrades other bioactive peptides such as GIP. DPP-4 is also present in high levels of hepatocytes, and the liver degrades much of the remaining GLP-1. Thus, very little GLP-1 leaves the intestine intact, and even less makes it to the systemic circulation.<xref ref-type="bibr" rid="article-21154.r12">[12]</xref>&#x000a0;Neutral endopeptidase 24.11 (NEP 24.11) is another enzyme that catabolizes GLP-1.&#x000a0;It is a zinc metallopeptidase expressed in several locations, particularly in the kidneys. However, its contribution to GLP-1 degradation only becomes clear following inhibition of DPP-4, as otherwise, most of the GLP-1 reaching the kidneys is already degraded by DPP-4.<xref ref-type="bibr" rid="article-21154.r14">[14]</xref>&#x000a0;Proteolysis by DPP-4 limits the half-life of endogenous GLP-1 to 1-5 minutes. Analogs of GLP-1 in clinical use are thus chemically modified to be resistant to the effects of this enzyme and, therefore, have much longer half-lives than endogenous GLP-1 (eg, liraglutide, exenatide). Another mechanism of prolonging the actions of GLP-1, apart from degradation-resistant synthetic analogs, is the inhibition of their degradation by the action of the class of drugs called DPP-4 inhibitors (eg, sitagliptin, saxagliptin, vildagliptin).</p>
      </sec>
      <sec id="article-21154.s8" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>The&#x000a0;role of preproglucagon is still under study, and it has probable different clinical applications, but currently, no routine test is performed in the clinical setting.</p>
      </sec>
      <sec id="article-21154.s9" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Enteroglucagon was once implicated in the pathogenesis of diabetes after pancreatectomy. These have also been described in a rare functional pancreatic neuroendocrine tumor, which may be located in the pancreas itself or in the small intestine, where they correlate with slight intestinal hypertrophy. A case report exists describing the trophic effects of enteroglucagon (now known to be due to GLP-2) in a patient with an endocrine tumor in the kidney.<xref ref-type="bibr" rid="article-21154.r15">[15]</xref></p>
      </sec>
      <sec id="article-21154.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>GLP-1 analogs are now used in the management of diabetes.<xref ref-type="bibr" rid="article-21154.r16">[16]</xref>&#x000a0;These agents can potentiate endogenous insulin release in response to oral glucose loads with only a minor risk of hypoglycemia&#x000a0;compared to sulfonylureas. Examples include long-acting GLP-1 agonists such as liraglutide, which are resistant to degradation by the enzyme dipeptidyl-peptidase-4 (DPP-4), and short-acting agonists like lixisenatide. Exenatide, another GLP-1 agonist, is available as both an immediate-release and an extended-release formulation. DPP-4 inhibitors inhibit the degradation of endogenous GLP-1 by DPP-4 and thus increase the half-life of the endogenous product. Examples include sitagliptin, saxagliptin, and linagliptin, among others. The efficacy of linagliptin may be adversely affected by CYP3A4 or P-glycoprotein inducers such as rifampin or St. John&#x02019;s wort, thus requiring the use of alternative agents that are not pharmacodynamically affected by changes in CYP-450 drug metabolism.<xref ref-type="bibr" rid="article-21154.r17">[17]</xref>&#x000a0;GLP-2 analogs are currently emerging as a treatment for short-bowel syndrome due to their trophic effects on the small intestine.<xref ref-type="bibr" rid="article-21154.r18">[18]</xref>&#x000a0;Currently, teduglutide, a novel GLP-2 analog, is being tested for use in this condition, seen in patients who have undergone extensive small bowel resection and subsequently lack sufficient small bowel absorptive area to keep up with the production of digestive juices and intake of foods and fluids.<xref ref-type="bibr" rid="article-21154.r19">[19]</xref></p>
      </sec>
      <sec id="article-21154.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21154&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21154">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21154/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21154">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21154.s12">
        <fig id="article-21154.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Intestinal Epithelium With L Cells Present. This image shows the intestinal epithelium where L cells are present. Contributed by B Bordoni, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="L-cells" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21154.s13">
        <title>References</title>
        <ref id="article-21154.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SUTHERLAND</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>DE DUVE</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas.</article-title>
            <source>J Biol Chem</source>
            <year>1948</year>
            <month>Sep</month>
            <volume>175</volume>
            <issue>2</issue>
            <fpage>663</fpage>
            <page-range>663-74</page-range>
            <pub-id pub-id-type="pmid">18880761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ketterer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eisentraut</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Distribution of immunoassayable glucagon in gastrointestinal tissues.</article-title>
            <source>Metabolism</source>
            <year>1966</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>865</fpage>
            <page-range>865-7</page-range>
            <pub-id pub-id-type="pmid">5923522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Dee</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Habener</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1982</year>
            <month>Jan</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-9</page-range>
            <pub-id pub-id-type="pmid">7043459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunawardene</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Corfe</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Staton</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Classification and functions of enteroendocrine cells of the lower gastrointestinal tract.</article-title>
            <source>Int J Exp Pathol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>219</fpage>
            <page-range>219-31</page-range>
            <pub-id pub-id-type="pmid">21518048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holst</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Enteroglucagon.</article-title>
            <source>Annu Rev Physiol</source>
            <year>1997</year>
            <volume>59</volume>
            <fpage>257</fpage>
            <page-range>257-71</page-range>
            <pub-id pub-id-type="pmid">9074764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kleinman</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raufman</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.</article-title>
            <source>J Biol Chem</source>
            <year>1992</year>
            <month>Apr</month>
            <day>15</day>
            <volume>267</volume>
            <issue>11</issue>
            <fpage>7402</fpage>
            <page-range>7402-5</page-range>
            <pub-id pub-id-type="pmid">1313797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The incretin hormone GLP-1 and mechanisms underlying its secretion.</article-title>
            <source>J Diabetes</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>753</fpage>
            <page-range>753-765</page-range>
            <pub-id pub-id-type="pmid">27287542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nauck</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Incretin hormones: Their role in health and disease.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>20 Suppl 1</volume>
            <fpage>5</fpage>
            <page-range>5-21</page-range>
            <pub-id pub-id-type="pmid">29364588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drucker</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.</article-title>
            <source>Cell Metab</source>
            <year>2018</year>
            <month>Apr</month>
            <day>03</day>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>740</fpage>
            <page-range>740-756</page-range>
            <pub-id pub-id-type="pmid">29617641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pocai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Unraveling oxyntomodulin, GLP1's enigmatic brother.</article-title>
            <source>J Endocrinol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>215</volume>
            <issue>3</issue>
            <fpage>335</fpage>
            <page-range>335-46</page-range>
            <pub-id pub-id-type="pmid">23019069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Albrechtsen</surname>
                <given-names>NJW</given-names>
              </name>
              <name>
                <surname>Gabe</surname>
                <given-names>MBN</given-names>
              </name>
              <name>
                <surname>Rosenkilde</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Oxyntomodulin: Actions and role in diabetes.</article-title>
            <source>Peptides</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>100</volume>
            <fpage>48</fpage>
            <page-range>48-53</page-range>
            <pub-id pub-id-type="pmid">29412831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.</article-title>
            <source>Ann Pediatr Endocrinol Metab</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-26</page-range>
            <pub-id pub-id-type="pmid">28443255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mentlein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gallwitz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.</article-title>
            <source>Eur J Biochem</source>
            <year>1993</year>
            <month>Jun</month>
            <day>15</day>
            <volume>214</volume>
            <issue>3</issue>
            <fpage>829</fpage>
            <page-range>829-35</page-range>
            <pub-id pub-id-type="pmid">8100523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plamboeck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Deacon</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.</article-title>
            <source>Diabetologia</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>9</issue>
            <fpage>1882</fpage>
            <page-range>1882-90</page-range>
            <pub-id pub-id-type="pmid">16025254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gleeson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Polak</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function.</article-title>
            <source>Gut</source>
            <year>1971</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>773</fpage>
            <page-range>773-82</page-range>
            <pub-id pub-id-type="pmid">4941684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kalia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Recent updates on GLP-1 agonists: Current advancements &#x00026; challenges.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>108</volume>
            <fpage>952</fpage>
            <page-range>952-962</page-range>
            <pub-id pub-id-type="pmid">30372907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graefe-Mody</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Retlich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Friedrich</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and pharmacodynamics of linagliptin.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2012</year>
            <month>Jul</month>
            <day>01</day>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>411</fpage>
            <page-range>411-27</page-range>
            <pub-id pub-id-type="pmid">22568694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeppesen</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2012</year>
            <month>May</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>159</fpage>
            <page-range>159-71</page-range>
            <pub-id pub-id-type="pmid">22570676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21154.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gabe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Short bowel syndrome: the role of GLP-2 on improving outcome.</article-title>
            <source>Curr Opin Clin Nutr Metab Care</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>526</fpage>
            <page-range>526-32</page-range>
            <pub-id pub-id-type="pmid">19474717</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
